ASCO: Roche's Alecensa stays on top of Xalkori with long-term survival showing

Roche made a splash at ASCO three years ago with data showing that its Alecensa could top Pfizer’s Xalkori at keeping ALK-positive lung-cancer at bay. This time, it’s back with long-term data showing it can best Xalkori at keeping patients alive, too.